The Association for Clinical Oncology (ASCO) calls on Congress to pass legislation that will prevent devastating reimbursement cuts to Medicare services set to begin on January 1. Failure to do so will significantly compromise patient access to lifesaving cancer care during an ongoing and unprecedented pandemic.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
ASCO has been notified of a recent safety notice relating to BLENREP (belantamab mafodotin - blmf) under the Food and Drug Administration’s (FDA) Risk Evaluation and Mitigation Strategy (REMS) program.
On November 22, 2021, the Food and Drug Administration approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
On November 19, 2021, the Build Back Better Act passed the U.S. House of Representatives with a vote of 220-213. The legislation contains significant health care provisions, some of which are outlined here.
The Centers for Medicare & Medicaid Services (CMS) is applying the Merit-based Incentive Payment System (MIPS) automatic extreme and uncontrollable circumstances (EUC) policy to all individually eligible MIPS clinicians for the 2021 performance year (PY) due to COVID-19.
A new book, “A New Deal for Cancer: Lessons from a 50-year War,” highlights the progress against cancer in the United States over the past half century and what may lie ahead. In a collection of essays, leading oncology experts, including doctors, policymakers, and academics, examine how policy, politics, and law can and should help advance progress against cancer, and how the obstacles in the path of continued progress can be dismantled.
Due to the ongoing impact of COVID-19, the Centers for Medicare & Medicaid Services (CMS) is allowing clinicians, groups, virtual groups, and Alternative Payment Model (APM) Entities to request MIPS performance category reweighting for PY 2020 under the EUC policy until November 29, 2021.
The Association for Clinical Oncology (ASCO), along with nearly 30 other stakeholder groups, sent a letter to congressional leadership urging lawmakers in both chambers to protect patient access to potentially life-saving cancer care by passing legislation to prevent massive cuts to Medicare reimbursement for radiation oncology.
The Association for Clinical Oncology (the Association) commends Representatives DeGette and Upton for introducing the 21st Century Cures 2.0 Act, which would increase diversity of clinical trials, expand patient access to telehealth, and provide a much-needed boost in funding to research institutions
The American Medical Association's House of Delegates recently approved a resolution committing the AMA to strongly advocate against the application of sequestration to Medicare services, including to drugs administered under Medicare Part B, which would result in significant reimbursement cuts for Medicare providers. ASCO strongly advocated for the AMA HOD to pass this resolution.
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
The American Society of Clinical Oncology (ASCO) is currently recruiting practices to participate in measures testing for a variety of efforts, including re-endorsing existing measures by the National Quality Forum (NQF). In addition to ensuring the highest level of quality care for individuals with cancer and advancing the specialty of oncology, participating practices will be provided with some financial support for their participation and ASCO members will also be awarded FASCO points.
On November 4, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA) issued an Emergency Temporary Standard (ETS) as an interim final rule outlining the COVID-19 vaccination policy for employers of 100 or more staff.
American Society of Clinical Oncology (ASCO) members who are practicing oncologists may have recently received an email inviting them to participate in an American Medical Association’s (AMA) Specialty Society Relative Value Scale (RVS) Update Committee (RUC) survey. This important survey will help ASCO, in collaboration with the RUC, recommend relative value units to the Centers for Medicare & Medicaid Services (CMS) for certain services.
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Hospital Outpatient Prospective Payment System (OPPS) final rule. The Association for Clinical Oncology (ASCO) will analyze the rule in greater detail in the coming days, while initial highlights are outlined here.